characteristics.text: 2024-01-01
characteristics.characteristic: ENA first public
characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: Clinical institute of Genomic Medicine, University Medical Centre Ljubljana
characteristics.characteristic: INSDC center name
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS20608292
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-14282:EN035
characteristics.characteristic: Submitter Id
characteristics.text: 34
characteristics.unit: year
characteristics.characteristic: age
characteristics.text: ArrayExpress
characteristics.characteristic: broker name
characteristics.text: not collected
characteristics.characteristic: collection date
characteristics.text: human
characteristics.characteristic: common name
characteristics.text: Protocols: Endometrial biopsies were collected with a catheter (Rampipella, RI.MOS., Mirandola, Italy) from the uterine cavity between days 21 and 23 of the menstrual cycle under sterile conditions prior to the IVF procedure.  Total RNA was isolated from endometrial tissue using the RNeasy Mini Kit reagent kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions (https://www.qiagen.com). The purity of the isolated RNA was assessed using a NanoDrop 2000c spectrophotometer (Nanodrop Technologies, Wilmington, Delaware, USA). Integrity was determined on an Agilent 2100 bioanalyzer using an RNA 6000 Nano LabChip kit (Agilent Technologies, Santa Clara, California, USA).  The library was prepared using the TruSeq RNA reagent kit (Illumina, San Diego, California, USA) according to the manufacturer's instructions. This protocol was used to convert the whole RNA into a fragment library for next-generation sequencing. After removal of ribosomal RNA using the Ribo-Zero rRNA approach (Illumina, San Diego, California, USA), the remaining RNA was purified, fragmented and the first strand cDNA (complementary DNA) was synthesized using reverse transcriptase and random oligonucleotide primers. This was followed by the synthesis of a second cDNA chain with deoxyuridine triphosphate nucleotides. The double-stranded DNA, which was terminated with blunt ends, was further adenylated at the 3'end in the next step. Sequences with molecular barcodes and adapters were added to the ends of the double-stranded cDNA to bind to the surface of the flow cell. Fragments with ligated adaptors at both ends were selectively enriched by 15 cycles of PCR.
characteristics.characteristic: description
characteristics.text: adult
characteristics.characteristic: developmental stage
characteristics.text: polycystic ovary syndrome
characteristics.characteristic: disease
characteristics.text: not collected
characteristics.characteristic: geographic location (country and/or sea)
characteristics.text: EN035
characteristics.characteristic: individual
characteristics.text: not applicable
characteristics.characteristic: isolate
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: endometrium
characteristics.characteristic: organism part
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: female
characteristics.characteristic: sex
characteristics.text: EN035
characteristics.characteristic: title
characteristics.text: none
characteristics.characteristic: treatment